华润三九医药股份有限公司

Core Viewpoint - The company is preparing for its 2025 annual general meeting, where it will discuss and vote on significant proposals, including related party transactions and the expected amount of daily related transactions for 2026 [1][19]. Group 1: Meeting Proposals - Proposal 1 involves related party transactions, requiring abstention from voting by related shareholders [1]. - Proposal 2 is a special resolution that requires approval from more than two-thirds of the voting rights at the meeting [1]. - The company will separately count votes from minority investors and disclose the results publicly [1]. Group 2: Meeting Registration Details - Registration for the meeting will take place from December 22 to December 25, 2025, from 9:00 AM to 4:30 PM [2]. - The registration location is at the Huaren Sanjiu Pharmaceutical Industrial Park [3]. - Attendees must bring relevant identification documents for registration [4]. Group 3: Voting Procedures - Shareholders can participate in voting through a network platform provided by the company, using the Shenzhen Stock Exchange trading system and internet voting system [6]. - Voting will occur on December 26, 2025, during specified trading hours [9]. - The internet voting system will be available from 9:15 AM to 3:00 PM on the same day [11]. Group 4: Related Party Transactions - The company estimates that the total amount of daily related transactions for 2026 will not exceed RMB 494,427.53 million, with sales to related parties expected to be RMB 446,292.11 million and purchases at RMB 48,135.42 million [20]. - For the period from January to October 2025, sales to related parties amounted to RMB 221,140.90 million, while purchases totaled RMB 24,624.21 million [20]. Group 5: Related Party Overview - The controlling shareholder of the company is China Resources Pharmaceutical Group, which is a wholly-owned subsidiary of China Resources Group [39]. - The company’s related parties include various subsidiaries involved in pharmaceutical operations, with significant assets and revenues reported for the year 2024 [23][24][25][27][28][33].